ReCode in the News
Press Releases
ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announcedthat the
ReCode Therapeutics to Participate in February Conferences
ReCode today announced that company management will participate in the upcoming February conferences...
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
Collaboration combines Intellia’s leading CRISPR-based platform, including its DNA writing technology, with ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP)to extend the reach
ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy for the Treatment of Primary Ciliary Dyskinesia
– Phase 1 study aims to evaluate safety and tolerability of a single ascending dose of RCT1100 in patients with PCD caused by mutations
Media Contacts
ReCode Therapeutics
Erica Jefferson
[email protected]
The Grace Communication Group
Tara Cooper
[email protected]
[email protected]
Investor Contact
Stern IRAnneMarie Fields
[email protected]
[email protected]
Presentations
Aerosolized lipid nanoparticle/mRNA therapy to treat patients with Cystic Fibrosis
2023 Cilia, Mucus and Mucociliary Interactions GRC
Publications & Abstracts
Featured News
Unshackling genetic medicines by enabling delivery beyond the liver
Nature Biopharma Dealmakers